Cargando…

NY-ESO-1 expression in solid tumors predicts prognosis: A systematic review and meta-analysis

BACKGROUND: New York esophageal squamous cell carcinoma 1 (NY-ESO-1) is a member of the cancer testis antigen family. NY-ESO-1 has documented potential as an effective target for cancer immunotherapy. The prognostic value of NY-ESO-1 expression in solid tumors, however, remains controversial because...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Huiyu, Chen, Datian, Wang, Runjie, Quan, Wen, Xia, Dandan, Mei, Jie, Xu, Junying, Liu, Chaoying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890322/ https://www.ncbi.nlm.nih.gov/pubmed/31770209 http://dx.doi.org/10.1097/MD.0000000000017990

Ejemplares similares

Low NDRG2 expression predicts poor prognosis in solid tumors: A meta-analysis of cohort study
por: Gu, Aiqin, et al.
Publicado: (2020)

High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review
por: Xia, Dandan, et al.
Publicado: (2018)

Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment
por: Zhou, Hong, et al.
Publicado: (2023)

NY-ESO-1 expression in DCIS: A new predictor of good prognosis
por: Coombes, R. Charles, et al.
Publicado: (2017)

First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors
por: Ishihara, Mikiya, et al.
Publicado: (2020)

Association between Alpha B-crystallin expression and prognosis in patients with solid tumors: A protocol for systematic review and meta-analysis
por: Yang, Minglan, et al.
Publicado: (2021)

Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis
por: Wang, Qianqian, et al.
Publicado: (2017)

Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors: A systematic review and meta-analysis
por: Wang, Bi-Cheng, et al.
Publicado: (2020)

Involvement of NY-ESO-1 and MAGE-A4 in the pathogenesis of desmoid tumors
por: Hashimoto, Kazuhiko, et al.
Publicado: (2023)

Tiam1 high expression is associated with poor prognosis in solid cancers: A meta-analysis
por: Ding, Jianlong, et al.
Publicado: (2019)

The relationship between Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 12 (SNHG12) expression in solid malignant tumors and prognosis of tumor patients: A systematic review and meta-analysis
por: Huang, Zixi, et al.
Publicado: (2020)

Prognostic role of high TET1 expression in patients with solid tumors: A meta-analysis
por: Ke, Qiwei, et al.
Publicado: (2020)

Prognostic value of HHLA2 expression in solid tumors: A meta-analysis based on the Chinese population
por: Zhang, Chuanmeng, et al.
Publicado: (2021)

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
por: Thomas, Remy, et al.
Publicado: (2018)

High expression COL10A1 promotes breast cancer progression and predicts poor prognosis
por: Zhou, Weijian, et al.
Publicado: (2022)

Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
por: Gong, Wenjie, et al.
Publicado: (2021)

Tumor-Infiltrating T Cells Correlate with NY-ESO-1-Specific Autoantibodies in Ovarian Cancer
por: Milne, Katy, et al.
Publicado: (2008)

Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma
por: Zhang, Zhen, et al.
Publicado: (2017)

Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis
por: Wei, Wei, et al.
Publicado: (2018)

Evaluation of X-Ray Repair Cross-Complementing Family Members as Potential Biomarkers for Predicting Progression and Prognosis in Hepatocellular Carcinoma
por: Mei, Jie, et al.
Publicado: (2020)

FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis
por: Chen, Datian, et al.
Publicado: (2018)

NF-κB Expression and Outcomes in Solid Tumors: A Systematic Review and Meta-Analysis
por: Wu, Dang, et al.
Publicado: (2015)

Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients
por: Kageyama, Shinichi, et al.
Publicado: (2013)

A pan-cancer analysis of the MAPK family gene and their association with prognosis, tumor microenvironment, and therapeutic targets
por: Qin, Yuan-Yuan, et al.
Publicado: (2023)

Deep phenotypic characterization of NY-ESO TCR engineered T cells and tumor in patients with advanced myeloma
por: Davila, Eduardo, et al.
Publicado: (2015)

Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients
por: Camisaschi, Chiara, et al.
Publicado: (2018)

TCR-Engineered Lymphocytes Targeting NY-ESO-1: In Vitro Assessment of Cytotoxicity against Tumors
por: Alsalloum, Alaa, et al.
Publicado: (2023)

Circulating tumor DNA predicts recurrence and assesses prognosis in operable gastric cancer: A systematic review and meta-analysis
por: Mi, Junjie, et al.
Publicado: (2023)

Correlation between tumor marker CA72-4 and prognosis of patients with gastric cancer: A protocol for systematic review and meta-analysis
por: Li, Minxia, et al.
Publicado: (2020)

Cancer‐testis antigens PRAME and NY‐ESO‐1 correlate with tumour grade and poor prognosis in myxoid liposarcoma
por: Iura, Kunio, et al.
Publicado: (2015)

Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysis
por: Cao, Lin-Lin, et al.
Publicado: (2017)

Identification of NY-ESO-1(157–165) Specific Murine T Cell Receptors With Distinct Recognition Pattern for Tumor Immunotherapy
por: Zhang, Helin, et al.
Publicado: (2021)

The high expression of CHD1L and its clinical significance in human solid tumors: A meta-analysis
por: Zhang, Long, et al.
Publicado: (2021)

Prognostic value of platelet-to-lymphocyte ratio in neoadjuvant chemotherapy for solid tumors: A PRISMA-compliant meta-analysis
por: Long, Yuming, et al.
Publicado: (2021)

NY-ESO-1 antibody as a novel tumour marker of gastric cancer
por: Fujiwara, S, et al.
Publicado: (2013)

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma
por: Giesen, Eva, et al.
Publicado: (2014)

NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target
por: Lai, Jin-Ping, et al.
Publicado: (2012)

Pushing forward in sarcoma with a new TCR targeting NY-ESO-1
por: Al-Marayaty, Rusul, et al.
Publicado: (2023)

Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4(+)T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma
por: Jäger, Elke, et al.
Publicado: (2000)

Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141(+) dendritic cells to activate naïve and memory NY-ESO-1-specific CD8(+) T cells
por: Masterman, Kelly-Anne, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kli4321v558ij4kgmrsnvephac